The global Intravenous Immunoglobulin Market size is expected to reach USD 21.1 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2022 to 2030. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.
The rising incorporation of subcutaneous
immunoglobulin in the treatment of primary immunodeficiency diseases as well as
in replacement therapy is anticipated to provide a growth platform to the
market in the next seven years. Moreover, the key market players are
focusing on breakthrough product introductions to expand their global
distribution network. For instance, Octapharma U.S. got FDA clearance in
July 2021 for Octagam 10%, its first intravenous immunoglobulin recommended for
the treatment of the immune-mediated inflammatory illness known as
dermatomyositis in adults.
The COVID-19 pandemic, which is currently in its last
stages, is expected to boost the worldwide market for intravenous
immunoglobulin. In India, for instance, Bharat Biotech is conducting a study to
create monoclonal antibodies as a potential COVID-19 treatment. The Council of
Scientific and Industrial Research (CSIR) has approved the project as part of
its New Millennium Indian Technology Leadership strategy. Moreover, COVID-19
has caused substantial issues for patients with mental and neurological disorders
due to their increased susceptibility to infection. For instance, in April
2021, Grifols, a key provider of plasma-derived medicines,
contributed to a research study in collaboration with both the NIH and NIAID,
to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among
outpatients. This is expected to provide a boost to the market growth in the
forecast period.
Key players are adopting strategic alliances to
sustain the competition. These initiatives include mergers & acquisitions,
collaborations, and new product developments. For instance, in March 2022,
Grifols' XEMBIFY has been approved in Europe, increasing access to novel
medicines. Grifols' clearance in Europe allows it to extend its breakthrough
European IG product range and offer patients and healthcare professionals
another crucial therapy solution for primary and secondary immunodeficiencies.
In February 2021, Pfizer gained US FDA clearance for the supplemental Biologics
License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure
adult patients with severe inflammatory demyelinating
polyneuropathy (CIDP).
Related Press Release@ Intravenous Immunoglobulin Market Report
Intravenous Immunoglobulin Market
Report Highlights
- The hypogammaglobulinemia application segment held the
third-largest revenue share in 2021. This can be attributed to the
increasing demand for immunoglobulin replacement therapies to treat
hypogammaglobulinemia diseases, which is driven by rising awareness levels
amongst patients and increasing incidences of the disease
- The hospital pharmacy distribution channel segment dominated the
market with a revenue share of over 55.0% in 2021 owing to the large
network of hospitals and the convenient range of products that are easily
accessible through hospital pharmacies. Furthermore, hospitals offer
fast reimbursement, treatment, and proper care to a large number of
patients, enabling a surge in the prevalence of patients selecting
hospital pharmacies
- The specialty pharmacy distribution channel segment is anticipated
to expand at a lucrative CAGR of 8.9% during the forecast period as
specialty pharmacies enable easy treatment at home
- North America held the largest share in terms of revenue in 2021
due to the presence of a well-regulated healthcare system, the larger pool
of target population, and high patient awareness pertinent to the plasma
protein products
- Asia Pacific is expected to register a significant CAGR of 8.4%
over the forecast period owing to the increasing number of patients with
bleeding disorders and the growing number of CIDP patients
- Countries such as India, China, and South Africa are expected to
witness significant growth over the forecast period owing to improving
healthcare facilities, rising healthcare expenditure, and growing public
awareness regarding immune deficiency disorders
- The Kawasaki disease application segment is expected to expand at a
lucrative CAGR of 9.6% from 2022 to 2030 owing to the massive adoption of
IVIG treatment in the aforementioned disease management
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment